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programs has led to a need for robust measurements and assay valida-
tion techniques for analyses of biological samples. The importance of
solid methodologies for biomarker assessment is heightened by the
fact that new drugs frequently only offer modest beneﬁt and that
many potential biomarkers are continuous variables, the application of
which relies on data interpretation, with the risk of subjectivity bias,
to establish thresholds. Patritumab is a fully human anti-human epider-
mal growth factor receptor 3 (HER3) antibody that inhibits HER3 from
binding to HRG (Mendell et al., 2015). In the HERALD phase II trial,
before data unblinding but after subject enrollment, heregulin (HRG)
was prospectively declared to be the predictive biomarker for
patritumab efﬁcacy. Advanced non-small cell lung cancer (NSCLC)
patients previously treated with at least one chemotherapy regimen
were randomized to erlotinib plus patritumab (high- or low-dose) or
erlotinib plus placebo (Mendell et al., 2015). Testing a single primary
predictive biomarker hypothesis to identify those patients most likely
to beneﬁt from patritumab was a secondary objective of the trial and
HRG was identiﬁed as a continuous biomarker to predict outcome.
Members of the HER family of receptor tyrosine kinases (RTK) and
their respective ligands constitute a robust biologic system that plays
a key role in the regulation of cell-proliferative growth, survival, and dif-
ferentiation (Ma et al., 2014). HER3 transactivation via dimerization
with other RTKs is frequently observed in various malignancies, includ-
ing NSCLC. Binding of the alpha and beta forms of neuregulin 1, collec-
tively known as HRG, exposes a dimerization arm in the extracellular
domain of HER3 and promotes receptor–receptor interactions (Ma
et al., 2014; Carraway et al., 1994). HER3 contains six phosphotyrosine
binding sites for the p85 subunit of PI3K, the greatest number of all
HER familymembers, and is amajor cause of treatment failure in cancer
therapy (Ma et al., 2014; Fedi et al., 1994). Recently, the role of HER3 in
primary and acquired resistance to EGFR-targeted or other targeted
therapies in NSCLC patients has attracted considerable attention (Ma
et al., 2014; Torka et al., 2014). Since HER3 lacks or has weak intrinsic
kinase activity, targeting it with blocking antibodies that inhibit HRG
binding is one strategy currently being investigated in order to over-
come therapeutic resistance (Ma et al., 2014).
In the study by Mendell et al., although no progression-free survival
(PFS) beneﬁt was observed overall with the addition of patritumab toDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.02.005.
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HRG-high patients treated with patritumab and erlotinib had signiﬁ-
cantly improved PFS compared with patients treated with erlotinib
alone in both the high- and low-dose arms (Hazard Ratio (HR), 0.37
[95%CI, 0.16–0.85] and 0.29 [95%CI, 0.13–0.66]) (Mendell et al., 2015).
No PFS beneﬁt was observed in HRG-low patients. An exploratory
analysis suggested that high HRG expression might also be a negative
prognostic factor in patients treated with single-agent erlotinib
(Mendell et al., 2015).
The role of HRG expression as a marker of HER3 activity has been
previously reported. Constitutive activation of HER3 signaling can
occur in the absence of direct genetic activation of HER3 or HRG while
HER3 activation does not occur as a result of mutation or ampliﬁcation
of the HER3 co-receptors EGFR or HER2. Chronic HER3 signaling is driv-
en by high level and potentially autocrine expression of HRG (Holmes
et al., 1992). When HRG and HER3 expressions were proﬁled in more
than 750 patients with head and neck squamous cell carcinoma, high-
level expression of HRG was associated with constitutive activation of
HER3, deﬁning an actionable biomarker for interventions targeting
HER3 (Shames et al., 2013).
Since the arrival of erlotinib and geﬁtinib, metastatic EGFR positive
lung cancer patients can be offered therapeutic alternativeswith proven
superiority over standard platinum-based chemotherapy (Rosell et al.,
2013). Testing for EGFR mutations to guide patient selection for EGFR
inhibitors, in all patients with advanced-stage adenocarcinoma, regard-
less of sex, race, smoking history, or other clinical risk factors, is highly
recommended (Lindeman et al., 2013). As commented by Mendell
et al., the use of a prospective–retrospective approach applied to a single
predictive biomarker hypothesis has the advantage of avoiding a high
false-positive rate due to multiple comparisons when multiple bio-
marker hypotheses are evaluated on an equal footing in an exploratory
fashion (Mendell et al., 2015). But are statistical simulations able to
dismiss the confounding interactions that EGFR-sensitizing mutations
could have on the HRs observed in the study? Some readers may also
wonder why, in a study of primarily erlotinib treatment where samples
were obtained from most patients, EGFR mutations were not assessed?
Clinical trials with EGFR inhibitors designed without using EGFR muta-
tion status, as an enrolment criterion should not be an acceptable prac-
tice anymore. Finally, having lost N50% of samples for analyzing HRG
mRNA, can we safely conclude that high HRG mRNA and not HER3 ex-
pression levels are correlated with patritumab efﬁcacy?
Although technological improvements in terms of specimen acquisi-
tion and processing have beenmade, muchwork remains to be done tothe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tion, processing and storage procedures, attributable largely to the
long-standing success of formalin-ﬁxed parafﬁn-embedded tissue anal-
ysis as the standard in diagnostic pathology. There is an ongoing trend
to improve standardization of procedures for biomarker development
in oncology that involves academia, professional organizations, and in-
dustry. Identiﬁcation and widespread use of biomarkers will ensure
that patients receive the best possible therapeutic strategies, thereby
avoiding unnecessary treatments and associated toxicities, and reduc-
ing total health costs. Increased awareness of HER3 function in cancer
progression and tumor recurrence following drug resistance has several
implications for future lines of investigation. High expression of HRG
seems to accurately deﬁne a population of tumors that may have an
oncogenic dependency on ligand-activated signaling via HER3
(Mendell et al., 2015). Based on the results of the Mendell et al. study,
a two-part phase III study (NCT02134015) has been initiated to
examine patritumab plus erlotinib treatment in EGFR wild-type
patients with advanced NSCLC. Part A will enroll subjects with any
HRG value to further reﬁne the HRG cutoff level while evaluating the
efﬁcacy of patritumab plus erlotinib versus erlotinib in the HRG-high
group. Part B will enroll only HRG-high (as per revised criteria) patients
to evaluate efﬁcacy and safety of patritumab plus erlotinib versus
erlotinib.
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